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Introduction: Depletion of limbal stem cells leads to a debilitating condition known as limbal stem cell deficiency,
characterised by impaired corneal wound healing and poor vision. The aim of this study was to determine whether
delivering progenitor cells on a contact lens is a viable and effective alternative to current transplantation
techniques, which are complicated by biological and xenogeneic materials.
Methods: Sixteen eyes of 16 patients who had total (n = 14) and partial (n = 2) limbal stem cell deficiency (chemical
burns, five eyes; iatrogenic causes, four eyes; aniridia, three eyes; trachoma-induced, two eyes; contact lens over-wear,
one eye; and cicatrising conjunctivitis, one eye) and who had failed prior therapy were recruited prospectively into the
study. Autologous limbal (n = 7) or conjunctival epithelial (n = 9) biopsies were harvested from patients and placed on
the concave surface of silicone hydrogel contact lenses. Cells were expanded in culture with autologous serum and
transplanted onto the ocular surface.
Results: Restoration of a transparent avascular and clinically stable corneal epithelium was attained in 10 of 16 eyes (63%)
at a median follow-up time of 2.5 years (range of 0.8 to 5.8 years). Although minor complications occurred in two eyes of
two patients because of contact lens insertion or removal, these were not associated with long-term sequelae.
Conclusions: This is the first and largest study to evaluate the mid-term outcomes of autologous limbal/conjunctival
stem cell transplantation via a US Food and Drug Administration-approved contact lens, demonstrating that delivery of
ocular progenitor cells via this procedure offers a viable, effective, and xeno-free alternative to current transplantation
methodologies.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN012607000211460. Registered 17 April 2007.Introduction
The corneal epithelium is maintained by stem cells (SCs)
presumed to reside in the transitional zone between the
cornea and conjunctiva, also known as the limbus [1]. De-
pletion of limbal epithelial stem cells (LESCs) through
damage to their microenvironment (the niche) or aberrant
functional modification can result in limbal stem cell defi-
ciency (LSCD), a disease characterised by impaired cor-
neal wound healing, loss of vision, and chronic pain [2].* Correspondence: n.digirolamo@unsw.edu.au
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unless otherwise stated.LSCD is classified as either partial (involving a sector) or
total (affecting the entire cornea) and encompasses a
range of aetiologies. Surgical treatment via keratoplasty is
deemed ineffective as these patients lack the SCs needed
to re-epithelialise their corneal surface.
Since the pioneering work of Kenyon and Tseng [3]
(1989) on limbal tissue transplantation, the field has grown
exponentially. Moreover, substantial research efforts have
been devoted to developing carrier substrates that facilitate
cell expansion ex vivo and integration during transplant-
ation. To date, the most commonly used substrate for LESC
transplantation is human amniotic membrane (HAM), and
reported success rates in patients with LSCD range fromThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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anti-angiogenic and contains SC support factors, its dis-
advantages include its semi-opaqueness, donor-to-donor
variability, expensive screening, and strict guidelines for
preparation and storage [7-9]. Fibrin has been trialed as an
alternative carrier; however, its short setting time poses diffi-
culties in manipulating the membrane film during surgery
[10,11]. Several other biomaterials have been trialed in
ex vivo or animal models, or both, albeit to differing degrees.
These scaffolds include silk fibroin [12,13], collagen shields
[14], anterior human lens capsule [15], and silicone hydro-
gen contact lenses (CLs) [16-18]. Recent studies have shown
that cells labeled ex vivo can adhere to CLs and are able to
successfully transfer, survive, and proliferate after delivery
[19,20]. Moreover, our clinical trial using this system showed
that CLs could be used as a carrier and substrate for in vivo
delivery of ocular surface cells, with a 100% success rate re-
corded in three patients with LSCD 12 months after the
procedure [21]. Since we first reported our technique, bio-
degradable membranes which eliminate the need to remove
the carrier have also been developed; however, they are still
in the preliminary stages of trialing [22]. Advantages of CLs
as a substrate include its transparency, mechanical stability,
cost-effectiveness, and non-immunogenic nature. Currently,
comparisons between different transplantation methodolo-
gies for managing LSCD are lacking and there is an increas-
ing need for xeno-free expansion to meet the increasingly
strict regulatory demands. Herein, we report the short- to
mid-term outcomes of using CLs for xeno-free culture and
expansion and as a carrier for ocular surface SC transplant-
ation in 16 patients with LSCD.
Methods
Clinical trial
The clinical trial was registered in Australia (ACTRN-
012607000211460) and approved by the South Eastern
Sydney Local Health District Human Research Ethics Com-
mittee (SESLHD HREC-07/025). The SESLHD Executive
Committee approved the follow-up arm of the trial (HREC-
13/139). All components of this study were carried out in
accordance with the Declaration of Helsinki. The protocol
for using human cells and tissue was approved by the Uni-
versity of New South Wales Human Research Ethics Com-
mittee (HREC-06290). Informed consent was obtained
from all patients.
Patients with limbal stem cell deficiency
The study design was a prospective non-comparative case
series comprising a sample size of 16 eyes from 16 patients
with LSCD who had failed prior therapy. Patients were re-
cruited between 2007 and 2011 and were referrals to the
Corneal Unit at the Sydney Eye Hospital (Sydney,
Australia), Eye Clinic at the Prince of Wales Hospital
(Randwick, Sydney, Australia), or private rooms (BondiJunction, Sydney). Patients with severe total or partial
LSCD were included in the study, and LSCD was diag-
nosed clinically [10,23]. Clinical features that distinguished
these patients included recurrent or persistent epithelial
defects, corneal fibrovascular pannus, and chronic inflam-
mation [10,23]. For partial LSCD, patients had failed all
prior medical therapy and had at least 6 clock hours (180
degrees) of whorl-like epitheliopathy, opaque epithelium
arising from the limbus, and superficial neovascularisation
or conjunctivalisation or both [24,25]. Photographs were
taken to document these features. Impression cytology was
not performed as it can induce painful persistent epithelial
defects with the risk of infection or increased inflammation
or both [10]. Patients with total or partial LSCD were in-
cluded if they had failed all prior therapy, which included
autologous serum drops, preservative-free lubricants,
therapeutic CL wear, limbal tissue allografts, HAM trans-
plants, superficial keratectomy, and conventional corneal
grafts. Table 1 summarises the baseline demographic fea-
tures of our patients.
Cell culture, contact lens insertion, and post-operative
follow-up
Multiple (two or three) autologous epithelial biopsies (ap-
proximately equal to 1 to 2 mm2) were taken from either
the superior limbal region or superior conjunctival fornix of
the contralateral eye under local anesthesia (Minims Tetra-
caine Hydrochloride 1%; Chauvin Pharmaceuticals, Bausch
& Lomb, Kingston-Upon-Thames, UK) based on data sug-
gesting that cells from the superior forniceal explants grow
more effectively [26,27]. Serum was isolated from 20 mL of
whole blood taken at the time of biopsy by standard
venipuncture. Each biopsy was placed on the concave sur-
face of a siloxane-hydrogel extended-wear CL (Lotrafilcon
A; CIBAVision, Duluth, GA, USA) in 24-well culture plates
(Corning Inc., Corning, NY, USA) in Eagle’s minimum es-
sential medium containing 10% autologous serum with
antibiotic supplements as previously detailed [16,21]. Cul-
tures were kept in an isolated incubator set to 37°C with
5% CO2, and growth was monitored daily with media chan-
ged on alternate days. When cells reached confluence (9 to
16 days), patients were scheduled for the procedure and the
cell-coated CL transported to the operating theatre in
growth media in cold storage (4°C to 10°C). This ensured
that cell activity could be preserved in the event of delays in
theatres. Cells emerging from tissues explanted on CLs
have previously been phenotyped and shown to express
several key ocular surface SC markers [21].
Patients with unilateral conditions had limbal and con-
junctival biopsies harvested from separate sites, and pa-
tients with bilateral disease received cells from conjunctival
biopsies. In patients with unilateral conditions, limbal biop-
sies were cultured on CLs; however, two patients (cases 5
and 15) had limbal biopsies that did not grow. Thus, these
Table 1 Patient demographics and pre-operative characteristics
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Table 1 Patient demographics and pre-operative characteristics (Continued)
16. 80/F R B 9 T Cicatrising conjunctivitis;
ocular surface toxicity from
glaucoma medication
CE/IOL, blepharoplasty Dexa minims, cellufresh
tears, timolol/latanoprost
Nil
All patients were additionally prescribed minims chloramphenicol 0.5% post-operatively (not included in table). Asterisk (*) indicates previous surgical procedures to treat limbal stem cell deficiency (LSCD). Days in
culture refers to the time to establish a reasonable number of cells on the contact lens before transplantation. BD, twice daily dosing; BV, blood vessel; CE/IOL, cataracts extraction/intraocular lens insertion; cellufresh
tears, preservative free carboxymethylcellulose sodium 5 mg/mL; CL, contact lens; dexa minims, minims dexamethasone sodium phosphate 0.1%; DSEK, Descemet’s stripping endothelial keratoplasty; EDTA,
ethylenediaminetetraacetic acid chelation therapy for band keratopathy; FML, flurometholone 1%; HAM, human amniotic membrane; PK, penetrating keratoplasty; predsol minims, minims prednisolone sodium phosphate
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biopsies to avoid the risk of SC failure in the donor eye be-
ing induced by a repeat limbal biopsy.
Prior to insertion of the CL, 5% betadine was applied to
the eye and a total superficial keratectomy, including re-
moval of limbal epithelium, was performed to remove any
irregular epithelium or pannus or both [21]. The CL with bi-
opsy and expanding cells was inserted onto the patient’s
ocular surface under topical anesthesia (Minims Benoxinate
Hydrochloride 0.4%; Chauvin Pharmaceuticals, Bausch &
Lomb). Penetrating keratoplasty (PK) was performed prior
to CL insertion as indicated in patients who had endothelial
failure with stromal edema (cases 6, 8, and 14) and stromal
scarring (case 12) reducing vision. Post-operatively, patients
continued to take prior systemic and topical therapy. For
prophylaxis against infection, each patient was prescribed
Minims Chloramphenicol 0.5% (Chauvin Pharmaceuticals,
Bausch & Lomb), which was applied for 4 weeks. Twelve
patients also received Minims Dexamethasone sodium
phosphate 0.1% (Chauvin Pharmaceuticals, Bausch &
Lomb) tapered over the course of 1 month. Two patients
were continued on Minims Prednisolone sodium phos-
phate 0.5% (Chauvin Pharmaceuticals, Bausch & Lomb)
(Table 1). The topical steroid regime was determined by
the treating physician according to the degree of post-
operative inflammation.
Follow-up and assessment of outcome
Ophthalmological evaluations after the procedure were per-
formed at days 1 and 7 and then at 1, 3, 6, and 9 months.
Six-month follow-ups were scheduled during the following
year and yearly visits thereafter. Each visit involved taking a
medical history, recording ocular symptoms, imaging the
eye, and performing Snellen’s test for best-corrected visual
acuity (BCVA), slit-lamp examination, tear film assessment,
ocular surface staining with fluorescein, and tonometry. Pa-
tients’ medical records were reviewed, and data were re-
corded on a proforma and entered into an electronic
database. Success was defined as ocular surface stability
and visual improvement unless otherwise limited by pre-
existing or concomitant disease. Two authors (SW and SB)
determined ocular surface stability from clinical examin-
ation, clinical photographs, and medical notes. Independent
grading of each patient was also performed from clinical
photographs by author ND. In alignment with previously
published reports [4,14,23,28], restoration of corneal epithe-
lium, reduction of neovascularisation, and the absence of
recurrent or persistent epithelial defects (PEDs) were the
parameters used to determine ocular surface stability.
Corneal epithelialisation was defined on the basis of
transparency without epithelial defects on slit-lamp exam-
ination and the absence of abnormally high fluorescein
permeability. Partial success was defined as improvements
in subjective ocular symptoms or BCVA or both with astable central corneal epithelium and no PEDs despite the
presence of peripheral epithelial whorl-staining or recurrent
vascularisation, even if not as extensive as at the time of ad-
mission [14]. Treatment failure was defined as recurrence of
LESC failure with conjunctivalisation of the ocular surface.
Statistical analysis
Survival probability of grafts was analyzed by Kaplan-
Meier and the log-rank test. Graft survival began at the
time of transplant, and an event was defined as failure
or success at the last follow-up. Descriptive statistics
were used to summarise all continuous and categorical
variables. Analyses were performed by SPSS 21.0 soft-
ware (IBM SPSS Statistics, version 21; IBM Corporation,
Armonk, NY, USA).
Results
Cell culture and growth of biopsies
Cells began to emerge as early as 2 days in culture irre-
spectively of whether limbal or conjunctival tissue biop-
sies were used (Figure 1A and B). Eventually, a halo of
cells of similar morphology surrounded each limbal or
conjunctival biopsy, and the migratory front of expand-
ing cells reached the edge of the CL by 9 to 16 days
post-explanting (Figure 1C-E). In four (25%) out of 16
patients, a second set of biopsies was harvested for cul-
ture purposes as insufficient growth developed from the
first. No signs of SC failure were observed in any donor
eye. No other complications were noted in regard to the
culture component. Prior to transplantation, an aliquot
of media from each culture was tested for mycoplasma
contamination; however, none returned a positive read-
ing (Figure 1F).
Patient characteristics
Sixteen eyes from 16 patients were enrolled in the study be-
tween 2007 and 2011. The mean age at follow-up was 62 ±
17 years (range of 28 to 85), and the male-to-female ratio
was 10:6. Table 2 summarises the post-operative characteris-
tics and outcomes of patients enrolled in the trial. The most
common aetiologies were chemical burns (31%), iatrogenic
causes (25%), and aniridia (19%). Other underlying aetiol-
ogies were trachoma-induced LSCD (cases 4 and 9), CL
over-wear (case 14), and cicatrising conjunctivitis due to
ocular surface toxicity from glaucoma medications (case 16).
Ocular surface stability
Restoration of ocular surface stability was seen in 12 eyes
(75%) at 1 year and 11 eyes (69%) at 2 years with a cumula-
tive survival of 63% after a median follow-up time of 2.5 ±
1.2 years (range of 0.8 to 5.8) (Figures 2A and 3A and B). Bi-
opsies of conjunctival origin had a higher cumulative
survival (78%) compared with the survival rate displayed by
limbal biopsies (43%); however, this was not a statistically
Figure 1 Cell growth from limbal and conjunctival biopsies. Phase-contrast images of limbal (A, C, D) and conjunctival (B, E) biopsies excised from
patients with limbal stem cell deficiency and cultured over a specific period (see panel label for case identification number and time in culture). Although
cultures displayed ample proliferation activity, some grafts failed (A-C) whereas others were successful (D and E) at last follow-up. A representative
polymerase chain reaction for mycoplasma (F) on conditioned media derived from cultured cells from patient 12 (S2) is shown. S1 (positive control) shows a
band at 259 base pairs (bp), and S3 is a negative control.
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(Figure 2B, P= 0.06). The outcomes of three of these pa-
tients (cases 1 to 3) at the 1-year follow-up were published
previously [20], and all continue to maintain a stable ocular
surface at the 5- to 6-year follow-up. Case 1, though still
with visual improvement from baseline, has recently devel-
oped central subepithelial scarring and increasing epithelial
irregularity. A small area of localised inferonasal band kera-
topathy adjacent to the limbus developed in case 2, with
endothelial decompensation, and has occasionally developed
local ulceration associated with the band keratopathy. One
eye (case 14) was deemed a partial success, having achieved
a transparent central corneal epithelium with no recurrent
ulcers or PEDs or both, complete resolution of ocular pain,
and improved visual acuity (hand movements to 6/90). This
was despite a localised region (fewer than 2 clock-hours) ofsuperior-temporal whorl-like corneal staining, which
remained stable at the 2-year follow-up period (Figure 3C
and D). When analysed according to the aetiology of LSCD,
patients with iatrogenic causes experienced a 100% success
rate (four out of four cases) compared with a 20% success
(one out of five cases) for patients with chemical burns.
Aniridia was associated with a 67% success rate (two out of
three cases), and patients with trachoma were both deemed
successful. When analysed according to the severity of
LSCD, the three patients with partial LSCD experienced a
100% success rate and the patients with total LSCD experi-
enced a 54% success rate.
Visual acuity and ocular symptoms
In 90% of patients deemed successes or partial successes,
ocular symptoms (pain, burning, and photophobia) resolved
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SCT + SK - 6/60 + 1 6/45 Central clear, peripheral pannus Glaucoma, DE,
subepithelial scarring
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2 L 5.67 biopsy retained in
cornea
SCT + SK DSEK (endothelial
decompensation), CE/
IOL











4 C 2.92 (lost
to follow-
up)
Nil SCT + SK - 6/45 6/36 Central clear, superior peripheral
pannus
Subepithelial scarring S
5 C 4.67 Second biopsy, no/
poor growth
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poor growth
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Table 2 Post-operative characteristics and outcomes of ocular surface stem cell transplantation via contact lens delivery (Continued)
14 C 1.92 Nil SCT + PK HM 6/90 Central clear, mild subepithelial







15 C 1.67 Nil SCT + SK EDTA 6/36 6/90 Central clear LK, stromal scarring S
16 C 1.67 Nil SCT + SK Cyclodiode laser 2/60. 1/60 Corneal ulcer, PED DE, stromal scarring,
glaucoma
F
BV, blood vessel; C, conjunctival; CE/IOL, cataract extraction/intraocular lens; CF, counting fingers; CL, contact lens; DE, dry eye; DSEK, Descemet’s stripping endothelial keratoplasty; EDTA, ethylenediaminetetraacetic
acid chelation therapy for band keratopathy; F, failure; HAM, human amniotic membrane; HM, hand movements; L, limbal; LK, lipid keratopathy; LP, light perception; PED, persistent epithelial defect; PEEs, punctate












Figure 2 Kaplan-Meier survival curve. Sixteen eyes of 16 patients who underwent ocular surface epithelial transplantation via contact lens delivery
were assessed for graft survival. (A) Total or partial success was attained in 63% of the cases. (B) Stratified by epithelial origin of the cell graft total or
partial success was attained in 78% of cases after transfer of conjunctival biopsies (n = 9) and 43% of cases after transfer of limbal biopsies (n = 7).
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ocular disease limited visual improvement in most patients
(Table 2). Fifty percent of patients who achieved a successful
outcome attained improved visual acuity (at least one line)
and the biopsies in each of these five patients were all of
conjunctival origin. Twenty percent maintained their pre-
operative visual acuity (for example, patient 9 maintained a
BCVA of 6 out of 6 after receiving cells from a limbal bi-
opsy, and patient 11 maintained a BCVA of 2 out of 60 after
a conjunctival biopsy). Thirty percent of the patients deemed
successes experienced a decline in BCVA by 4, 3, and 1 line
(cases 2, 15, and 3, respectively). The BCVA of patient 2 de-
clined 3 years after SC transplantation because of endothe-
lial decompensation and was subsequently treated with
Descemet’s stripping endothelial keratoplasty (DSEK). The
decline in visual acuity of patient 3 was attributed to pro-
gressive cataract (untreated because of patient preference
and corneal scarring limiting visual potential), and patient
15 to lipid keratopathy. Though deemed failures due to re-
currence of epithelial defects, patients 6 and 8 both achieved
improvements in their BCVA attributed to successful treat-
ment of concomitant ocular disease (Table 2). By excluding
these patients with confounding co-morbidities from ana-
lysis, we demonstrated that 71% of the remaining seven pa-
tients with a conjunctival biopsy had an improved BCVA
and that 33% had a stable BCVA. This compares favourably
with 75% of the remaining four patients with limbal biopsies
having a stable BCVA and 25% a reduced BCVA.
Characteristics of failed transplants
Failed transplants were characterised by recurrence of con-
junctivalisation, vascularisation, corneal epithelial defectsor a combination of these (Figure 3F and H). Of the fail-
ures, the underlying aetiology was chemical burns in 67%
(four out of six cases), and aniridia and cicatrising conjunc-
tivitis were the cause in the other two patients. Of the fail-
ures, 50% had a second set of biopsies harvested prior to
the cell transfer therapy because of insufficient growth
from the first explants. In 67% of failures, biopsies were of
limbal rather than conjunctival origin. Most failures (67%)
occurred within the first 4 months after transplantation;
two eyes (cases 6 and 16) failed in the following 1 to 2
years, both complicated by ocular surface toxicity due to
glaucoma medications. Fifty percent of the failures had
prior grafts (to treat LSCD) that had also failed.
Discussion
This study found that transplantation of autologous limbal
and conjunctival epithelial cells via CL delivery success-
fully restored the ocular surface in 63% (10 out of 16
cases) of patients with LSCD at a median follow-up time
of 2.5 ± 1.2 years (range of 0.8 to 5.8). The reported suc-
cess rate of cultivated autologous limbal epithelial cell
transplantation (LSCT) ranges from 33% to 100% with a
mean of 75% at 2-year follow-up [4,6,10,23,28-31]. Al-
though our results were lower than the overall mean suc-
cess rate [4,6], they are within the range reported by
others [4,6,10,23,28-31]. Furthermore, recent clinical trials
[10,32] have shown that repeat autologous cultivated
LSCT following failed primary transplantation surgery
successfully replenishes the ocular surface. As our tech-
nique is repeatable, a second cell transfer via CL in failed
transplants could also increase the success rate of our
technique in future studies. The variability in results from
Figure 3 Clinical features of patients who underwent cell transplantation. Slit-lamp photographs of successful transplants in patient 2 (A, B) and
patient 14 (C, D) before treatment (A, C) and at last follow-up—(B) 5.6 years and (D) 1.9 years—with restoration of an intact transparent corneal epithelium
and reduced vascularisation (B). Notably, a localised region of superior-temporal whorl-like staining (obscured by the eyelid) was evident on clinical
examination in patient 14 (D). Slit-lamp photographs of failed transplants in patient 8 (E, F) and patient 13 (G, H) before treatment (E, G) and at last
follow-up—(F) 2.6 years and (H) 2 years—with an irregular corneal epithelium and recurrence of epithelial defects.
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pre-operative condition; the majority of patients in our
study failed all prior treatment regimens, including cor-
neal grafts and limbal tissue transplants, and some even
had coexistent ocular disease.
Although autologous limbal epithelial biopsies are the tis-
sue of choice when expanding SCs for transplantation, the
limited availability of limbal tissue particularly in cases of
bilateral disease has necessitated the use of alternative tis-
sue sources. In our study, autologous conjunctiva was used
as a source of epithelial SCs for transplantation in cases of
bilateral disease, and successful outcomes were reported inseven (78%) out of nine patients, unexpectedly higher than
the 43% success rate for cells of limbal origin (Figure 2B).
Although these results did not reach significance, the
higher success rates in patients receiving conjunctival com-
pared with limbal cells could be attributable to the slightly
larger biopsies that were obtained from conjunctival tissue.
Larger biopsies were harvested from the conjunctiva as
there was no risk of inducing SC failure in the donor eye.
Notably, this explanation is purely speculative as conjunc-
tival cells in culture did not grow faster than the limbal
equivalents and there are no published reports indicating
that cells from larger biopsies are associated with improved
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that detachment of limbal explants from their scaffolds re-
sults in unsuccessful primary cultures [33], potentially
explaining the failure of cell growth from limbal explants in
cases 5 and 12.
In 25% of our patients, cells failed to grow from explants
and a second set of biopsies was harvested before successful
ex vivo expansion. Although many studies do not disclose
the number of detachments, Sangwan and colleagues [31]
(2011) reported successful cellular growth from tissue ex-
plants in all 200 eyes when cultured on HAM, suggesting
that a synthetic CL scaffold may not be as effective as a
native substrate for expansion. The ability to make direct
comparisons with their study, however, is hindered by the
heterogeneity of disease. Whereas patients in the study by
Sangwan and colleagues were diagnosed with unilateral ocu-
lar surface burns, 44% of the patients in the present study
had bilateral LSCD and many cases also had had previous
surgeries to the donor eye, potentially impacting the prolifer-
ative capacity of harvested cells. Additionally, the culture
technique of Sangwan and colleagues, which involved shred-
ding presumably larger segments of donor limbal tissue into
small pieces and explanting these over the substrate, could
have contributed to the higher success rate of their culture
system. Regardless, our study addresses the challenge of
biopsy detachment since multiple autologous samples were
obtained and the CL substrate is easily available, allowing
more than one culture to be initiated with minimal
difficulties.
In relation to lineage origin, the conjunctival epithelium
is perhaps the cell type most closely related to the corneal
epithelium [34]. Kawasaki and colleagues [35] found a
population of keratin-12-positive cells in the conjunctival
epithelium, presumed to be ectopically residing corneal
epithelial cells. Additionally, Majo and colleagues [36] dis-
covered that porcine corneal and conjunctival holoclones
shared an ocular gene expression profile, supporting our
proposition that conjunctival and limbal epithelial cells
can be interchanged. Notably, their results have raised
controversy on multiple levels; however, they noted two
differentially expressed genes between these epithelia from
over 20,000 assessed. Although the precise mechanisms of
how conjunctival cells re-establish the ocular surface are
not known, the conjunctiva contain its own SCs that may
have the ability to transdifferentiate when exposed to
corneal-specific signals [37,38]. For example, Shapiro and
colleagues [39] found that, after 4 to 5 weeks, transplanted
conjunctival epithelial cells morphologically resembled
corneal epithelium. It should be noted, however, that these
findings are controversial, and subsequent studies showed
that transplanted conjunctival cells retained lineage-specific
features [40,41]. Despite this, transplanted conjunctival
epithelium has been shown to successfully regenerate the
ocular surface in rabbit models of total LSCD [38,42,43]as well as in patients with LSCD [44-46]. Notably, end-stage
limbal stem cell failure is characterised by conjunctivalisa-
tion of the ocular surface. However, the conjunctival cells
transferred in our study were epithelial in origin, and iso-
lated from an area of conjunctiva that was not affected by
disease, which may have accounted for their transparency
after engraftment. Further conjunctival epithelial cells alone,
without the vascularised conjunctival stroma were utilised
for our patients. The present study demonstrates the effect-
iveness of conjunctival-derived progenitor epithelial cells in
transplants, suggesting that even if conjunctival cells do not
transdifferentiate, they may acquire a corneal-like phenotype
under the culture conditions provided.
Although the primary aim of restoring corneal epithelial
integrity and thus resolving ocular discomfort was achieved,
improved visual acuity as the secondary outcome measure
was attained in 50% of the successful transplants with at
least a one-line improvement in BCVA and 20% maintain-
ing their pre-operative visual acuity (Table 2). This was
attributed to the majority of patients having pre-existing cor-
neal scarring or concomitant ocular disease limiting vision
or both. Most (90%) patients with successful transplants re-
ported complete resolution of their ocular symptoms (burn-
ing, photophobia, or discomfort), and one patient (case 11)
complained of some (albeit reduced) discomfort, potentially
attributable to his coexisting dry eye.
The cause of graft failure in patients with LSCD is
poorly understood. Li and colleagues [47] have recently
shown that limbal niche and stromal cells are important
in supporting LESCs; thus, damage to the stromal niche
microenvironment could contribute to failures in some
patients since SC transfer does not address this anatomical
and structural modification. Curiously, we and others [48]
observed a higher failure rate in patients with chemical in-
juries, the cause of which is unknown but could be due to
excessive niche damage. Furthermore, of the six failed
transplants in our study, four failed within the first 4
months and two eyes failed in the following 1- to 2-year
period, both complicated by ocular surface toxicity due to
glaucoma medications. Additional investigations are re-
quired to determine whether glaucoma medication could
be revised prior to and during a specific period post-cell
therapy to increase the survival probability of grafts in pa-
tients with coexisting severe glaucoma. Indeed, since our
study commenced, a wider range of glaucoma medications
with less potential for ocular surface toxicity have become
available [49].
Minor complications occurred with CL insertion and re-
moval in two patients. In patient 1, we noted that the CL
rolled under the superior lid. However, since our procedure
involves harvesting multiple biopsies, a second cell-laden CL
was readily available and this was inserted over the patient’s
cornea the following day. The option of a replacement graft
is attractive and advantageous as it reduces the need to re-
Bobba et al. Stem Cell Research & Therapy  (2015) 6:23 Page 12 of 14biopsy, re-culture cells, re-schedule the procedure, and delay
treatment for the patient. In case 9, a small defect occurred
upon removal of the CL with stripping of superficial corneal
epithelial cells; however, this resolved within 24 hours and
was not associated with any long-term sequelae. In a third
patient (case 2), the biopsy integrated onto the patient’s cor-
nea and the transplant was deemed a success at 5.7 years.
Retention of the biopsy on the ocular surface was a positive
prognostic factor in this patient, but if integration occurred
over the visual axis, sight could have been affected. Although
it has been recognised that CL wear can be associated with
severe limbal SC failure [24], this occurs with long-term
wear; the total time of lens wear in our patients was 2 weeks.
Notably, irrespectively of the type of graft, once the lens was
removed from the patients’ ocular surface, it contained few
remnant cell colonies [21].
We acknowledge several limitations of our study. Firstly,
our investigation included a small sample size and a hetero-
geneous patient population. The differing aetiologies, pre-
operative condition, and concomitant ocular morbidities
limit the potential to make direct comparisons with previ-
ously published studies [48,50]; however, most reports share
similar constraints. Furthermore, with the exception of the
case report by Ang and colleagues [51], who compared the
efficacy of conventional and cultivated LSCT, almost no dir-
ect comparative studies for LSCT in human subjects have
been published. It is worth noting that success rates differ
significantly between patient groups with different aetiol-
ogies of LSCD and that further studies investigating specific
patient subtypes could reveal, for example, particular effect-
iveness of CL delivery for patients with iatrogenic-induced
LSCD. Furthermore, we included both total and partial
LSCD as patients in both groups had failed prior therapy.
Ideally, a control group should have been included; how-
ever, owing to the severity and progressive nature of LSCD,
it is unethical not to treat these patients. The lack of a stan-
dardised framework for the diagnosis and grading of LSCD
is also a limitation of our study and is a major concern of
most published work in this field [50,52]. An alternative ob-
jective scoring system could be developed on the basis of
impression cytology. However, this procedure has not been
routinely performed in clinical trials of LSCD [50] as it does
not significantly change the clinical diagnosis and exposes
patients to unnecessary pain and the risk of developing epi-
thelial defects [10]. Symptom-based questionnaires are also
flawed in the subjectivity of self-reporting and have not
been validated for patients with LSCD. Another limitation
of the present study is the inability to directly trace the fate
of transplanted cells. The mechanism by which SC trans-
plantation regenerates the corneal epithelium is not well
understood, and there is controversy surrounding whether
transplanted cells actually replenish the SC reserve or revive
any remaining quiescent SCs [10,29]. To address these crit-
ical questions, one could perform genetic lineage tracing[53] but these studies would need to be performed in la-
boratory animals, whereby marked SCs from transgenic
mice could be transplanted into wild-type recipients and
their long-term fate and function determined. We have
made progress in this area and recently established a
unique transgenic model whereby progenitor cells and their
progeny are traceable in live mice in real time [54].
The strengths of our study include its prospective nature
and length of follow-up. Our current findings substantiate
our earlier report [21] and confirm that SCs transplanted
via our novel CL delivery technique are maintained for
longer than 1 year, and successful outcomes were recorded
at a maximum follow-up of 5.8 years. The greatest advan-
tage of our approach is its autologous xeno-free nature and
the benefits in cost-effectiveness and accessibility over other
transplantation strategies. Additionally, CLs have been
shown to adsorb growth factors from serum and may act as
a slow-release device for SC-promoting factors at least dur-
ing the implantation period [55,56]. Recently, surface modi-
fications to CL polymers were demonstrated to enhance
the loading and transfer capacity of corneal epithelial cells
to wounded rabbit corneas [19,20].
Conclusions
In this study, we have shown that our technique of ocular
surface epithelial SC transplantation is a viable and promis-
ing alternative to current approaches, successfully regener-
ating a healthy ocular surface in patients with LSCD at
short- to mid-term follow-up in 63% of our patients. This is
consistent with similar studies using alternative transplant-
ation methodologies but our technique does not expose the
grafts to foreign human biological or xenogeneic materials.
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